SEC Form 4 · accession 0001214659-18-007654
HUMANIGEN, INC · HGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cameron Durrant
Officer — Chief Executive Officer · Director
Period of report
Dec 10, 2018
Accepted (ET)
Dec 12, 2018 · 4:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293310
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 par valueF1 | Dec 10, 2018 | A | 2,500 | $0.75 | A | 155,083 | D | |
| Common Stock, $0.001 par valueF1 | Dec 11, 2018 | A | 2,500 | $0.757 | A | 157,583 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The prices reported in Column 4 are weighted average prices. On December 10, 2018, Dr. Durrant purchased 2,500 shares in multiple transactions at prices ranging from $0.711 to $0.809, inclusive. On December 11, 2018, Dr. Durrant purchased an additional 2,500 shares in multiple transactions at prices ranging from $0.749 to $0.761, inclusive. The reporting person undertakes to provide to Humanigen, Inc., any security holder of Humanigen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.